

NEWSLETTER

May-August 2026, Issue 24

Highlights

I . Business Progress

- Viva Biotech Announces Its 2026 Interim Results: AI Sparks New Paradigm in Drug R&D, CDMO Commercial Manufacturing Accelerates Revenue Growth
- Viva Biotech's AIDD Team Publishes in JCIM: Automation of Complex Cyclic Peptide Molecular Dynamics Simulations in Pep2MARS
- Viva Biotech's Pep2MARS Advances Again: EnsembleCycPerm Overcomes the Bottleneck in Predicting Cyclic Peptide Permeability
- Viva Biotech Showcases Integrated AI-Driven Drug Discovery Strategy at thebell Pharma & Bio Forum 2026
- New Peptide Trends, New Breakthroughs—Viva Biotech's AI-Driven Frontier Innovation Forum on Peptide Therapeutics Concludes Successfully
- Viva Biotech Empowers Cancer Discovery Publication: Cryo-EM Fuels SBDD of HBS1L Molecular Glue Degradator TNG961
- Viva Biotech Contributes to Nature Communications Publication Revealing the Structural Basis of Selective IRAK4 Degradation by KT-474
- Viva Biotech Partner Impact Therapeutics Lists on HKEX, Marking a New Milestone in Synthetic Lethality
- Viva Biotech honored as "2026 China CRO Excellence Brand"

II . Portfolio Companies' Project Progress

- Positive Topline Results from the Pivotal Phase 3 REDUCE 2 Study of Pozdeutinurad in Gout
- Full-Life Technologies Announces US\$150 Million Financing to Accelerate Multiple Clinical Stage Assets and Manufacturing Capabilities
- HAYA Therapeutics Announces FDA Fast Track Designation for HTX-001
- TJ Biopharma and Biogen Announce Approval of Felzartamab for Marketing in China—the First Global Approval

Business Progress

Viva Biotech Announces Its 2026 Interim Results: AI Sparks New Paradigm in Drug R&D, CDMO Commercial Manufacturing Accelerates Revenue Growth

- On August 26, 2026, Viva Biotech Holdings Group (“the Group” or “the Company”, stock code: 1873.HK) announced that the Group's revenue amounted to RMB1,006.5 million and gross profit of RMB341.7 million, representing a gross margin of 34.0%. Overall, the Group's total revenue grew by approximately 21.0% year-on-year, primarily driven by the significant contribution from Langhua Pharmaceutical's CDMO business, under which one peptide project has entered the commercial production phase and the other small-molecule project has reached the PPQ phase. In addition, in the first half of 2026, the Group recorded a net profit of RMB100.9 million and an adjusted non-IFRS net profit of RMB128.3 million, both representing a decline compared with the corresponding period of last year. This was mainly attributable to a decrease in investment income contributions during the Reporting Period, unfavorable foreign exchange movements and increased R&D expenses associated with new business development.
- Since the first half of 2026, global investment and financing sentiment has continued its steady recovery. On this basis, the empowerment and driving force of AI across the entire drug R&D process are opening up new growth headroom for the Group's CRO business. During the Reporting Period, the Group was temporarily weighed on by unfavorable foreign exchange movements, which led to a modest dip in CRO revenue. However, after excluding the impact of exchange rate fluctuations and on a constant-currency basis under the same comparable methodology, CRO revenue still maintained a relatively stable underlying performance. In addition, the Group's CDMO business has two major commercial offerings in the pipeline, one of which, the peptide commercial project has already received FDA approval and has entered the commercial inventory ramp-up and production phase. The other small-molecule commercial project is currently in the PPQ (Process Performance Qualification) phase, with commercial launch expected in 2027. Together, these two projects will lay a solid foundation for the revenue growth of Langhua Pharmaceutical over the coming years. Anchored in innovative drug R&D, the Group's CRO and CDMO businesses continue to strengthen the empowerment and driving force of AI across its original drug discovery service platforms. Through innovation and deep integration of resources, the Group remains committed to providing clients with one-stop integrated services from early-stage structure-based drug discovery to commercial drug manufacturing.

Business Progress

Viva Biotech's AIDD Team Publishes in JCIM: Automation of Complex Cyclic Peptide Molecular Dynamics Simulations in Pep2MARS

- Recently, the AIDD team at Viva Biotech published their novel work in the *Journal of Chemical Information and Modeling* (JCIM) under the title "Pep2MARS: Automated Cyclic Peptide Parameterization for Molecular Dynamics and Compound Design". This paper was led by Dr. Yue Qian, Vice President and Head of the MARS (Multi-modality AI-rooted Solutions) at Viva Biotech (Shanghai), with Dr. Junhao Li, Project Manager at Viva Biotech, as the first author.
- The study addresses the long-standing challenge of parameterization in the preprocessing of complex cyclic peptides for molecular dynamics (MD) simulations. An automated modeling strategy based on "Block" chemical units is proposed, which incorporates cross-residue covalent couplings into the force-field parameter generation framework. This approach enables unified description and stable mapping of non-natural amino acids, complex side-chain cross-links, and multicyclic scaffolds. In this study, further validation through microsecond-scale MD simulations on the PCSK9 cyclic peptide system revealed that cyclic peptide activity does not depend solely on the conformational stability in the free state, but is closely related to conformational adaptability during binding, offering a new dynamic framework for interpreting the structure-activity relationships in complex cyclic peptides. Beyond enhancing the standardization and reproducibility of complex cyclic peptide simulations, this approach also provides critical computational infrastructure for high-reliability mechanistic validation following AI-driven sequence generation, structure prediction, and virtual screening, thereby accelerating the scaled construction of a closed-loop cyclic peptide drug design. Pep2MARS seamlessly integrates physics-based and AI-driven algorithmic frameworks, and aims to boost the success rate of complex molecular R&D through iterative optimization between computational modeling and wet-lab experiments.

Business Progress

Viva Biotech's Pep2MARS Advances Again: EnsembleCycPerm Overcomes the Bottleneck in Predicting Cyclic Peptide Permeability

- Viva Biotech's MARS (Multi-Modality AI-Rooted Solutions) AI algorithm team recently published an innovative study in the Journal of Chemical Information and Modeling (JCIM), entitled "*EnsembleCycPerm: Interpretable Modeling of Cyclic Peptide Permeability through Solvent-Dependent Conformational Ensembles*." The study was led by Dr. Yue Qian, Vice President and Head of the MARS Division at Viva Biotech (Shanghai), as the corresponding author. Sicheng Wen, an AI Algorithm Researcher in the MARS Business Unit, served as the first author and completed the work in collaboration with Dr. Yang Wang from Viva Biotech's CADD/AIDD platform.
- As an advanced tool developed by the MARS team, EnsembleCycPerm is an important component of Pep2MARS, Viva Biotech's proprietary suite of algorithms specifically designed for peptide discovery and optimization. Following the earlier development of Pep2MARS, which introduced an innovative solution to the challenges associated with molecular dynamics simulations of structurally complex cyclic peptides, the launch of EnsembleCycPerm represents another important advance by addressing a major bottleneck in cyclic peptide permeability prediction. As additional technologies from the MARS team are introduced, Viva Biotech aims to establish a comprehensive peptide design platform spanning the entire process from de novo design to multiparameter developability optimization.

Viva Biotech Showcases Integrated AI-Driven Drug Discovery Strategy at thebell Pharma & Bio Forum 2026

- Viva Biotech participated in thebell Pharma & Bio Forum 2026, held on April 27, 2026, in Seoul, Korea. At the forum, Dr. Derek Ren, CEO of Viva Biotech (Shanghai) Ltd., and Dr. Yue Qian, VP and Head of MARS (Multi-Modal AI-Rooted Solutions), delivered a keynote presentation titled "AI Meets Biotech: Revolutionizing First-in-Class & Best-in-Class Drug Discovery." The presentation highlighted Viva Biotech's approach to integrating artificial intelligence with structure-based drug discovery, with a focus on how AI-enabled modeling, experimental feedback, and closed-loop optimization can support the discovery of first-in-class and best-in-class therapeutics from target understanding to PCC generation.

New Peptide Trends, New Breakthroughs—Viva Biotech's AI-Driven Frontier Innovation Forum on Peptide Therapeutics Concludes Successfully

- At the Yaoweilai Conference, Viva Biotech hosted the "New Peptide Trends, New Breakthroughs—AI-Driven Frontier Innovation Forum on Peptide Therapeutics," engaging industry peers in discussions on the future landscape of peptide innovation. Moderated by Dr. Cai Jianhua, Senior Vice President of Viva Biotech (Shanghai), the forum brought together leading practitioners from industry and capital markets. Centered on AI-enabled peptide drug R&D and commercialization, participants engaged in an in-depth dialogue spanning technology, markets, and the industrial chain. View the highlight replay by [clicking here](#).

Business Progress

Viva Biotech Empowers Cancer Discovery Publication: Cryo-EM Fuels SBDD of HBS1L Molecular Glue Degradar TNG961

- Recently, the top-tier oncology journal Cancer Discovery (an AACR journal) published a research paper titled "*TNG961 is a selective oral HBS1L molecular glue degrader for the treatment of FOCAD-deleted cancers*". The study details the development of TNG961, a potent and selective oral molecular glue degrader of HBS1L, offering a novel precision medicine strategy for cancers characterized by FOCAD gene deletion. Viva Biotech played a pivotal role in this achievement by leveraging its advanced protein production and cryo-EM platform to resolve high-resolution structures that were essential for the structure-based drug discovery (SBDD) and optimization of TNG961.

Viva Biotech Contributes to Nature Communications Publication Revealing the Structural Basis of Selective IRAK4 Degradation by KT-474

- Recently, a new study published in Nature Communications has provided important mechanistic insights into targeted protein degradation (TPD). The research article, titled "*Structural basis for selective and potent degradation of IRAK4 by KT-474*", provides the first cryo-electron microscopy (cryo-EM) structure of the ternary complex formed by KT-474, IRAK4, and the E3 ligase receptor CRBN/DDB1. The findings explain why KT-474 remains a highly effective degrader despite displaying negative cooperativity during ternary complex formation—a result that challenges conventional assumptions in the PROTAC field and provides valuable guidance for the rational design of future targeted protein degraders. Viva Biotech played a key role in this study through close collaboration across its Protein Sciences, Cryo-EM, Bioassay, and Surface Plasmon Resonance (SPR) platforms, providing integrated technical expertise from protein production and biophysical characterization to structural determination.

Viva Biotech Partner Impact Therapeutics Lists on HKEX, Marking a New Milestone in Synthetic Lethality

- On May 13, 2026, Impact Therapeutics, Inc. (Stock Code: 07630.HK), a long-term partner of Viva Biotech, officially listed on the Main Board of the Hong Kong Stock Exchange (HKEX), becoming the "First Synthetic Lethality Oncology Stock on the HKEX." The IPO attracted widespread attention across the capital market, with its Hong Kong public offering oversubscribed by approximately 2,282 times. Prominent institutional investors, including Tencent Holdings, Lilly Asia Ventures (LAV), and Foresight Fund, participated as cornerstone investors.

Viva Biotech honored as "2026 China CRO Excellence Brand"

- From May 13 to 15, 2026, the 94th API China and the 92nd PharmChina were held concurrently at the National Exhibition and Convention Center in Shanghai. On the opening day, the authoritative industry ranking "2026 China CRO Excellence Brand" was officially unveiled. Viva Biotech was named to the list once again, recognized for its exceptional service quality, leading technical advantages, and continuous deep cultivation in innovative drug R&D and manufacturing, highlighting its solid brand influence and market recognition.

Portfolio Companies' Project Progress



Positive Topline Results from the Pivotal Phase 3 REDUCE 2 Study of Pozdeutinurad in Gout

- May 21, 2026 – Sobi® (STO: SOBI) announced positive topline results from the pivotal Phase 3 REDUCE 2 study (NCT06439602) evaluating pozdeutinurad (AR882), an investigational next-generation once-daily oral selective URAT1 inhibitor, in adults with gout including those with uncontrolled gout (also referred to as progressive gout) and inadequately controlled by existing therapies.
- Pozdeutinurad was added to Sobi's global development portfolio in February 2026 following its acquisition of Arthrosi, invested by Viva BioInnovator (VBI), a biotechnology company focused on developing treatments for gout, and further enhances Sobi's presence in this area.



Full-Life Technologies Announces US\$150 Million Financing to Accelerate Multiple Clinical Stage Assets and Manufacturing Capabilities

- May 19, 2026 – Full-Life Technologies ("Full-Life", the "Company"), invested by Viva BioInnovator (VBI), a fully-integrated global radiotherapeutics company, announced the completion of a US\$150 million financing package, comprised of approximately US\$109 million in Series D equity and US\$41 million in debt financing.
- Proceeds from the Series D round will be used to advance the Company's clinical stage assets, including potential best in class [225Ac]-FL-020 for prostate cancer and potential first in class [225Ac]-FL-261 for multiple solid tumor indications. The proceeds will also facilitate the initiation of GMP-grade 225Ac manufacturing at the Company's state-of-the-art facility in Belgium.



HAYA Therapeutics Announces FDA Fast Track Designation for HTX-001

- On July 28, 2026, HAYA Therapeutics SA ("HAYA"), a clinical-stage biotechnology company invested in and incubated by Viva Biotech, announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to its investigational product HTX-001 for the treatment of symptomatic non-obstructive hypertrophic cardiomyopathy (nHCM). HAYA is dedicated to developing precision RNA-guided therapeutics that reprogram disease-driving cellular states by targeting the regulatory genome, addressing common chronic and age-related diseases. HTX-001 is a first-in-class investigational long non-coding RNA (lncRNA) targeted therapy currently in Phase Ia/b clinical trials, with the first cohort of participants having completed dosing in May this year.

Portfolio Companies' Project Progress



TJ Biopharma and Biogen Announce Approval of Felzartamab for Marketing in China—the First Global Approval

- On August 13, 2026, TJ Biopharma, an investee company of Viva Biotech, and Biogen (Nasdaq: BIIB) jointly announced that felzartamab for injection (trade name: Jingfei®, hereinafter referred to as felzartamab) has received marketing approval from the National Medical Products Administration (NMPA) for use in combination with lenalidomide and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior line of therapy.
- Felzartamab is an anti-CD38 monoclonal antibody with broad therapeutic potential across various immune-mediated diseases and hematological malignancies. This approval represents the first globally approved indication for the product. TJ Biopharma spearheaded and successfully completed the clinical development and regulatory submission for felzartamab's indication of multiple myeloma in Greater China.
- In April 2026, TJ Biopharma entered into an agreement with Biogen, granting Biogen exclusive rights to felzartamab in Greater China, thereby unifying the product's global rights. This approval marks the formal launch of commercialization activities for felzartamab in China, and reflects the smooth progression of the product from clinical development and regulatory submission to commercialization and commercial supply.
- Under the agreement, Biogen will be responsible for the commercialization of felzartamab, while TJ Biopharma will oversee the commercial supply, leveraging its GMP-certified production base in Hangzhou. Both parties are advancing work at pace to bring this new treatment option available to patients as soon as possible.



Listing Date
B2019.05.09

Price (2026.9.18)
HKD 1.465

52 WK Range
HKD 1.04 – 3.27

Market Cap (2026.9.18)
HKD 3.067 Billion

Established in 2008, Viva Biotech (01873.HK) provides one-stop services ranging from early-stage Structure-Based Drug R&D to commercial manufacturing to global biopharmaceutical innovators. We offer leading early-stage to late-phase drug discovery expertise by integrating our dedicated team of experts, cutting-edge technology platforms, and state-of-the-art equipment in X-ray crystallization, Cryo-EM, DEL, ASMS, SPR, HDX, AIDD/CADD, and much more. Our business covers all aspects of therapeutic strategies and drug modalities, including small molecules and biologics across the pharma and biotech spectrum. The experienced chemistry team, led by senior medicinal chemists and drug discovery biologists, provides services for drug design, medicinal chemistry (hit to lead and lead optimization), custom synthesis, chemical analysis and purification, kilogram scale-up, peptide synthesis and corresponding bioassays. With our subsidiary, Langhua Pharma, we offer our worldwide pharmaceutical and biotech partners a one-stop integrated CMC (Chemical, Manufacturing, and Control) service from preclinical to commercial manufacturing. Additionally, Viva embedded an equity for service (EFS) model to high potential startups to address unmet medical needs.

As of June 30, 2026, Viva Biotech had cumulatively provided drug R&D and manufacturing services to 2,904 biotech and pharmaceutical clients around the world. We have invested and incubated 93 biotech start-ups in total. In the future, the company will continue to strengthen its technological barriers and improve R&D, production levels, and our service capacity to provide high-quality and diversified services for more drug discovery start-ups, as well as medium and large pharmaceutical enterprises around the world.

Investor & Media Enquiries

Viva Biotech Holdings website: www.vivabiotech.com
For further information, please contact: Tel: +86(0)21-6089 3288
Email: ir@vivabiotech.com